Representative publications:
"The pyrazolo [4, 3-c] pyrazole core as a novel and versatile scaffold for developing dual DYRK1A-CLK1 inhibitors targeting key processes of Alzheimer’s disease pathology." Bakalakou V-A, Mavroidi B, Kalampaliki A-D, Josselin B, Bach S, Skaltsounis A-L, Marakos P, Pouli N, Pelecanou M, Myrianthopoulos V*, Ruchaud S, Kostakis I-K*
European Journal of Medicinal Chemistry Reports, 2024, 100193.
"Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy." Angelopoulou A, Theocharous G, Valakos D, Polyzou A, Magkouta S, Myrianthopoulos V, Havaki S, Fiorillo M, Tremi I, Vachlas K, Nisotakis T, Thanos D-F, Pantazaki A, Kletsas D, Bartek J, Petty R, Thanos D, McCrimmon R-J, Papaspyropoulos A, Gorgoulis V-G
Molecular Cancer, 2024, 23:147.
"Novel aryl-substituted pyrimidones as inhibitors of 3-mercaptopyruvate sulfurtransferase with antiproliferative efficacy in colon cancer." Bantzi M, Augsburger F, Loup J, Berset Y, Vasilakaki S, Myrianthopoulos V, Mikros E, Szabo C, Bochet CG.
Journal of Medicinal Chemistry, 2021, 64, 6221-6240.
"Senescence and senotherapeutics: a new field in cancer therapy." Myrianthopoulos V, Evangelou K, Vasileiou PVS, Cooks T, Vassilakopoulos TP, Pangalis GA, Kouloukoussa M, Kittas C, Georgakilas AG, Gorgoulis VG.
Pharmacology & Therapeutics, 2019, 193, 31-49.
“Discovery and optimization of a selective ligand for the Switch/Sucrose Non-Fermenting-related bromodomains of Polybromo protein-1 by the use of virtual screening and hydration analysis.” Myrianthopoulos V, Gaboriaud-Kolar N, Tallant C, Hall ML, Grigoriou S, Brownlee PM, Fedorov O, Rogers C, Heidenreich D, Wanior M, Drosos N, Mexia N, Savitsky P, Bagratuni T, Kastritis E, Terpos E, Filippakopoulos P, Müller S, Skaltsounis AL, Downs JA, Knapp S, Mikros E.
Journal of Medicinal Chemistry, 2016, 59, 8787-8803.
“Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation.” Myrianthopoulos V*, Cartron P. F, Liutkevičiūtė Z, Klimasauskas S, Matulis D, Bronner C, Martinet N, Mikros E*.
European Journal of Medicinal Chemistry, 2016, 114, 390-396.
“Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases.” Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, MagiatiS P, Ferandin Y, Durieu E, Lozach O, Cappel D, Soudararahan M, Filippakopoulos P, Sherman W, Knapp S, Meijer L, Mikros E, Skaltsounis AL.
ACS Medicinal Chemistry Letters, 2013, 4, 22-26.
“An integrated computational approach to the phenomenon of potent and selective inhibition of Aurora kinases B and C by a series of 7-substituted indirubins.” Myrianthopoulos V, Magiatis P, Ferandin Y, Skaltsounis AL, Meijer L, Mikros E,
Journal of Medicinal Chemistry, 2007, 50, 4027-4037.
“Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin dependent kinases.” Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe M, Pearl L, Leost M, Greengard P, Meijer L.
Journal of Medicinal Chemistry, 2004, 47, 935-946.
For a complete list please visit the personal Scholar page.
"The pyrazolo [4, 3-c] pyrazole core as a novel and versatile scaffold for developing dual DYRK1A-CLK1 inhibitors targeting key processes of Alzheimer’s disease pathology." Bakalakou V-A, Mavroidi B, Kalampaliki A-D, Josselin B, Bach S, Skaltsounis A-L, Marakos P, Pouli N, Pelecanou M, Myrianthopoulos V*, Ruchaud S, Kostakis I-K*
European Journal of Medicinal Chemistry Reports, 2024, 100193.
"Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy." Angelopoulou A, Theocharous G, Valakos D, Polyzou A, Magkouta S, Myrianthopoulos V, Havaki S, Fiorillo M, Tremi I, Vachlas K, Nisotakis T, Thanos D-F, Pantazaki A, Kletsas D, Bartek J, Petty R, Thanos D, McCrimmon R-J, Papaspyropoulos A, Gorgoulis V-G
Molecular Cancer, 2024, 23:147.
"Novel aryl-substituted pyrimidones as inhibitors of 3-mercaptopyruvate sulfurtransferase with antiproliferative efficacy in colon cancer." Bantzi M, Augsburger F, Loup J, Berset Y, Vasilakaki S, Myrianthopoulos V, Mikros E, Szabo C, Bochet CG.
Journal of Medicinal Chemistry, 2021, 64, 6221-6240.
"Senescence and senotherapeutics: a new field in cancer therapy." Myrianthopoulos V, Evangelou K, Vasileiou PVS, Cooks T, Vassilakopoulos TP, Pangalis GA, Kouloukoussa M, Kittas C, Georgakilas AG, Gorgoulis VG.
Pharmacology & Therapeutics, 2019, 193, 31-49.
“Discovery and optimization of a selective ligand for the Switch/Sucrose Non-Fermenting-related bromodomains of Polybromo protein-1 by the use of virtual screening and hydration analysis.” Myrianthopoulos V, Gaboriaud-Kolar N, Tallant C, Hall ML, Grigoriou S, Brownlee PM, Fedorov O, Rogers C, Heidenreich D, Wanior M, Drosos N, Mexia N, Savitsky P, Bagratuni T, Kastritis E, Terpos E, Filippakopoulos P, Müller S, Skaltsounis AL, Downs JA, Knapp S, Mikros E.
Journal of Medicinal Chemistry, 2016, 59, 8787-8803.
“Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation.” Myrianthopoulos V*, Cartron P. F, Liutkevičiūtė Z, Klimasauskas S, Matulis D, Bronner C, Martinet N, Mikros E*.
European Journal of Medicinal Chemistry, 2016, 114, 390-396.
“Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases.” Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, MagiatiS P, Ferandin Y, Durieu E, Lozach O, Cappel D, Soudararahan M, Filippakopoulos P, Sherman W, Knapp S, Meijer L, Mikros E, Skaltsounis AL.
ACS Medicinal Chemistry Letters, 2013, 4, 22-26.
“An integrated computational approach to the phenomenon of potent and selective inhibition of Aurora kinases B and C by a series of 7-substituted indirubins.” Myrianthopoulos V, Magiatis P, Ferandin Y, Skaltsounis AL, Meijer L, Mikros E,
Journal of Medicinal Chemistry, 2007, 50, 4027-4037.
“Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin dependent kinases.” Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe M, Pearl L, Leost M, Greengard P, Meijer L.
Journal of Medicinal Chemistry, 2004, 47, 935-946.
For a complete list please visit the personal Scholar page.